|Bid||48.32 x 1000|
|Ask||48.40 x 3000|
|Day's Range||45.44 - 48.42|
|52 Week Range||45.44 - 74.49|
|Beta (3Y Monthly)||1.42|
|PE Ratio (TTM)||21.33|
|Earnings Date||Apr 23, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||77.83|
Gordon Haskett analyst Don Bilson seems to have a crystal ball—but what he’s really looking at is an array of unconventional corporate characteristics.
The OpiEnd Youth Challenge is the latest initiative as part of Centene's OpiEnd program, which addresses the national epidemic against opioid usage. Aligned with Centene's commitment to saving lives and improving outcomes, Centene aims to fight the opioid epidemic through quality enhancements and improved access to addiction treatment. "The widespread misuse of prescription and non-prescription opioids affects communities across urban, suburban, and rural areas," said Ken Yamaguchi, M.D., Executive Vice President, Chief Medical Officer for Centene.
Centene (CNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Centene, Turtle Beach, Callaway Golf and Acushnet highlighted as Zacks Bull and Bear of the Day
Centene or UnitedHealth Group: Which Is a Better Pick in April?(Continued from Prior Part)The leader in government-sponsored programs During its Centene-WellCare investor presentation, Centene (CNC) estimated fiscal 2019 proforma revenues of $97
Centene or UnitedHealth Group: Which Is a Better Pick in April?(Continued from Prior Part)Fidelis Care acquisition On July 2, 2018, Centene (CNC) issued a press release announcing the completion of the acquisition of Fidelis Care, a leading
Centene or UnitedHealth Group: Which Is a Better Pick in April?(Continued from Prior Part)Centene’s health insurance marketplace business In its 2019 Financial Guidance and Investor meeting presentation, Centene (CNC) highlighted its position as
Centene or UnitedHealth Group: Which Is a Better Pick in April?(Continued from Prior Part)EPS guidanceIn its fourth-quarter earnings conference call, Centene (CNC) guided for fiscal 2019 GAAP diluted EPS of $3.65–$3.83, higher than the previous
NEW YORK , April 9, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of WellCare Health Plans, Inc. ("WCG" ...
Centene or UnitedHealth Group: Which Is a Better Pick in April?(Continued from Prior Part)Revenue guidance In fiscal 2018, Centene (CNC) reported revenues of $60.12 billion, a YoY rise of 24.25%. According to the company’s fourth-quarter earnings
One concern is that the Trump Administration could wipe the Affordable Care Act, or Obamacare, from the books. Colin Scarola, an analyst at CFRA Research, thinks that's unlikely to happen, according to a March 28 article in the St. Louis Business Journal. Warning! GuruFocus has detected 4 Warning Signs with CNC.
Centene and Anthem, two dominant players in the health insurance space, are set to gain in an expanding industry. We will see here which one is better placed ahead of earnings.
Centene or UnitedHealth Group: Which Is a Better Pick in April?Stock price movementsOn April 5, Centene (CNC) closed at $55.84, 4.26% higher than its previous closing price, 12.67% higher than its 52-week low of $49.56, and 25.04% below its 52-week
CVS (NYSE:CVS) garnered some catching headlines recently that have the potential to move CVS stock. The company announced it would sell CBD (cannabidiol) products in some of its locations.Source: Mike Mozart via FlickrYes, CBD has been red hot, helping to drive the valuations of cannabis operators like Cronos Group (NASDAQ:CRON), Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB). It is a compound found in hemp that does not have TCH, which is the chemical that produces a high. Last year, Congress took CBD off the list for illegal substances by passing the Farm bill.While CBD offerings such as creams and sprays for the relief of pain will likely gin up some sales for CVS, it probably won't do too much to move the needle for the stock price. The fact is that the overall business is just too massive.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 High-Risk Stocks With Big Potential Rewards OK then, regardless of the CBD opportunity, might CVS still be an opportunity here? Well, from a valuation standpoint, the shares are definitely at dirt-cheap levels. Consider that the forward price-to-earnings multiple is a mere 7.4X. Oh, and the dividend is at an attractive 3.57.It's also important to note that CVS continues to crank out substantial cash flows. For last year, they came to $8.9 billion. And the company forecasts that they will increase from $9.8 billion to $10.3 billion this year. A big part of this will be due to the cost synergies from the acquisition of Aetna. The Issues with CVS StockYet when it comes to CVS, the low valuation and strong cash flows may not be enough. After all, the healthcare industry is rapidly undergoing wrenching changes. The latest evidence of this: Centene's (NYSE:CNC) $15 billion proposed acquisition for WellCare Health Plans (NYSE:WCG).The deal will create a powerhouse in the lucrative market for Medicare and Medicaid plans (there will be 22 million members and $97 billion in revenues). This will also put even more pressure on CVS, whose stock fell on the news.But there other headwinds that the company must deal with. For example, there remain major forces to lower pharmacy reimbursements and rebates.Here's how CEO Larry Merlo put it in the earnings call: "What we're experiencing in '19 is the declining benefit from new generics, lower brand inflation and the ongoing questions around rebates, along with some structural and CVS-specific challenges in the long-term care space."In fact, he believes that 2019 will be a year of "transition."But there is something else -- which could be a wildcard for CVS stock. It's what Amazon.com (NASDAQ:AMZN) might do. Last year, the company agreed to purchase PillPack, which is a next-generation online pharmacy. And because of this, the buzz is that AMZN is planning to make a major play for the drug distribution business. If so, this would likely have an adverse impact on CVS stock. Let's face it, investors have seen too many examples of how AMZN has disrupted industries. Bottom Line on CVS StockFor the most part, CVS's $69 billion acquisition of Aetna was a smart move. The vision of creating a fully integrated healthcare platform will likely provide for sustainable competitive advantages. The company is also taking innovative approaches of providing healthcare, such as with MinuteClinic locations and home visits for infusion servicesBut in the meantime, there are few material catalysts to get CVS stock back into gear. And again, there is the uncertainty regarding AMZN.So for now, the shares are probably not worth a purchase right now.Tom Taulli is the author of High-Profit IPO Strategies, All About Commodities and All About Short Selling. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Data Center Buys That Deliver Sizable Income * 7 High-Risk Stocks With Big Potential Rewards * 3 Marijuana Stocks to Watch as New York, New Jersey Delay Legalization Compare Brokers The post CVS Stock Is Not Nearly as Cheap as You Might Think appeared first on InvestorPlace.